Real-Time Post-Market Signal For Enhanced Surveillance

The U.S. Food and Drug Administration (FDA) issued a Request for Information (RFI) for market research on real-time or near-real-time post-market signals to enhance surveillance of regulated products. The FDA seeks to understand industry capabilities in providing timely alerts for safety events, product quality issues, supply disruptions, and public health signals. This RFI will help determine the availability of industry solutions, technical integration methods (e.g., APIs), and cost models. The FDA's existing surveillance systems, such as the Sentinel Initiative and Adverse Event Reporting Systems, could be complemented by these real-time signals. The RFI requests information on organizational overviews, signal types and data sources, detection and validation methods, technical integration approaches, security and privacy measures, cost information, and relevant experience. Specific signal types of interest include safety, product quality, supply chain, compliance, regulatory, and public health signals. The FDA will host a virtual Vendor Day on April 1, 2026, and responses to the RFI are due by April 7, 2026.

The FDA's "Real-Time Post-Market Signal Integration for Enhanced Surveillance" Vendor Day on April 1, 2026, aimed to explore how real-time signals from industry or external sources could enhance existing post-market surveillance. The FDA is interested in understanding industry capabilities, available signal types, technical transmission approaches (e.g., APIs), data sources, timeliness, and validation methods. Key areas of interest include signals related to safety, product quality, supply chain, compliance, and public health across various product categories. The event included a Q&A session where consolidated questions covered topics such as defining "real-time," preferred data sources and ownership models, signal validation, delivery mechanisms, and integration with existing FDA systems. The FDA is conducting market research, with RFI responses due by April 7, 2026, and explicitly stated that this Vendor Day was for planning and information-gathering only, not a solicitation or commitment.

The FDA is conducting market research for its Real-Time Post-Market Signal Integration for Enhanced Surveillance initiative to shift from reactive to proactive post-market surveillance. The goal is to identify safety signals within 24 hours or sooner across all FDA-regulated products by leveraging diverse, external data sources from vendors. The FDA is seeking actionable signals derived from vendor data and analytics capabilities, not full systems or platforms. Key themes include real-time detection, early awareness of emerging risks, cross-domain signal correlation, and public health impact. Vendors are expected to use their own data to detect and send signals via API, focusing on minimal, aggregated data while avoiding PII/PHI. The FDA is interested in both confirmed and early-stage signals and anticipates engaging multiple vendors for this signal-driven ecosystem.